In keeping with these data, MGCD0103 treatment did not induce any further inhibition of tumor growth or upregulation of p21 in Gli1-deficient cells (Fig. 3d,e), indicating that the antitumor properties of this drug are dependent on Gli1 in these cells. This evidence concerns the gene GLI1 and neoplasm.